Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (CEPAC-TDM)
An Open-Label, Randomized, Parallel Group Study of Patients Treated With Paclitaxel With Standard Dosing Versus Pharmacokinetic Guided Dose Adjustment in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)
This study will be performed on grade IIIb and grade IV Non Small Cell Lung Cancer (NSCLC) chemotherapy naive patients with good performance status. In course of this study, patients will be treated with Paclitaxel in combination with either Cisplatin or Carboplatin in a maximum of six therapy cycles. The goal of this study is to determine, if a pharmakokinetic driven dose adaptation of paclitaxel leads to a reduction of of grade 4 neutropenia, compared to conventional Paclitaxel dosing, without affecting progression free survival and overall survival.
This study includes a biomarker analysis and an optional genetic substudy.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Bochum、德国
- CESAR Study Center
-
Bonn、德国
- CESAR Study Center
-
Essen、德国
- CESAR Study Center
-
Gerlingen、德国
- CESAR Study Center
-
Großhansdorf、德国
- CESAR Study Center
-
Halle an der Saale、德国
- CESAR Study Center
-
Leer、德国
- CESAR Study Center
-
Löwenstein、德国
- CESAR Study Center
-
Munich、德国
- CESAR Study Center
-
Tübingen、德国
- CESAR Study Center
-
-
-
-
-
St. Gallen、瑞士、9007
- Kantonsspital St. Gallen
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Capable of understanding the protocol requirements and risks, and providing written informed consent.
- Patients with histologically confirmed NSCLC (stage IIIB-IV).
- Patients considered for first-line palliative chemotherapy with paclitaxel in combination with either cisplatin or carboplatin. Patients having received prior adjuvant non taxane-containing adjuvant chemotherapy are eligible.
- At least one bidimensionally measurable lesion according to RECIST 1.1.
- ECOG Performance Status (ECOG-PS) status ≤ 2.
- Female or male patients of 18 to 75 years of age at randomization
- Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum pregnancy test within 1 week prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods (condom).
- An absolute neutrophil count >1,500 cells/ mm3 (= 1.5 G/l).
- Platelet count > 100,000/mm3.
- Total bilirubin ≤ 2 x upper limit of normal.
- AST and ALT ≤ 2.5 x upper limit of normal, or ≤ 5 x upper limit of normal in case of liver metastases.
- Creatinine clearance (according to the Cockcroft-Gault formula) ≥30ml/min. For patients planned to receive Cisplatin: Creatinine clearance ≥60ml/min.
- Patients suffering from asymptomatic brain metastases can be enrolled in case corticosteroid therapy is not indicated. Prior irradiation must be completed at least 4 weeks prior to first cycle of treatment.
Exclusion Criteria:
- Serious concomitant systemic disorders (e.g., active infection, severe heart disease, uncontrolled hypertension or diabetes mellitus) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.
- A history of hypersensitivity reactions to drugs formulated in polyoxyethylated castor oil.
- Having received prior treatment with paclitaxel or cisplatin or carboplatin (other drugs/drug combinations are allowed).
- Concomitant treatment with any targeted drug (licensed or experimental) like bevacizumab or cetuximab.
- Any condition / concomitant disease not allowing chemotherapy with paclitaxel, the platinum compound (carboplatin or cisplatin) or required premedication for the treatment regimen.
- Pregnant/nursing women.
- Individuals known to be seropositive for human immunodeficiency virus, hepatitis C virus, hepatitis B surface antigen or syphilis.
- Treatment with cytotoxic or biologic agents or any experimental drug within the 4 weeks prior to beginning treatment on this study.
- Secondary malignancy within the last five years, with the exception of adequately treated carcinoma-in-situ of the uterine cervix, basal-cell carcinoma of the skin and pTa or pTis urothelial cancer.
- Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent.
- Preexisting neuropathy > grade I NCI-CTC.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Paclitaxel dosing according to SmPC
|
Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
|
|
实验性的:Individualized pharmacokinetically driven paclitaxel dosing
In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient.
In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
|
Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Grad 4 Neutropenia
大体时间:up to 6 weeks on treatment
|
The rate of grade 4 Neutropenia during the second treatment cycle between the conventional Paclitaxel dosing arm and pharmacokinetically driven Paclitaxel dosing arm is compared.
At the same time progression free survival and overall survival must not be affected.
|
up to 6 weeks on treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective tumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST v1.1)
大体时间:24 months
|
24 months
|
|
|
Progression free survival
大体时间:24 month
|
24 month
|
|
|
Overall survival
大体时间:24 month
|
24 month
|
|
|
Overall neutropenia
大体时间:24 month
|
Overall neutropenia ( i.e. during total chemotherapy duration) assessed from clinical hematology data and by model-based estimations of individual neutrophil curves
|
24 month
|
|
Hematological / non-hematological toxicites
大体时间:24 months
|
Hematological (leucocytopenia, anemia, thrombocytopenia) and non-hematological toxicities (e.g.
neurological, musculosceletal and gastrointestinal adverse events)
|
24 months
|
|
Cumulative dose and dose intensity of paclitaxel and platinum drug
大体时间:24 months
|
24 months
|
|
|
Incidence of changes from cisplatin to carboplatin and reasons thereof
大体时间:24 months
|
24 months
|
|
|
Overall rate of febrile neutropenia and hospitalization due to chemotherapy-associated adverse events
大体时间:24 months
|
24 months
|
|
|
Health economic analysis using QoL Questionnaires
大体时间:24 months
|
24 months
|
合作者和调查者
合作者
调查人员
- 学习椅:Markus Joerger, MD PhD、Central European Society for Anticancer Drug Research
- 研究主任:Ulrich Jaehde, PhD、Central European Society for Anticancer Drug Research
- 首席研究员:Frank Mayer, MD、Eberhard-Karls-Universität Tübingen
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.